IFN-τ Inhibitors
Chemical inhibitors of IFN-τ target various components of the JAK-STAT signaling pathway, which is essential for the protein's function. Janus kinase (JAK) inhibitor I, AG490, Ruxolitinib, Tofacitinib, Fedratinib, WHI-P154, and Lestaurtinib are all designed to inhibit the activity of JAK enzymes. By binding to the ATP-binding site of JAKs, these inhibitors prevent the phosphorylation and activation of STAT proteins, which normally transduce the signal from IFN-τ to elicit cellular responses. For example, Ruxolitinib selectively inhibits JAK1 and JAK2, disrupting the cascade that IFN-τ relies on to exert its effects. Similarly, Tofacitinib specifically inhibits JAK3, and in conjunction with JAK1, it plays a role in the signaling pathways initiated by IFN-τ. Fedratinib targets JAK2 and its inhibition is known to affect the JAK-STAT pathway as a whole, therefore reducing IFN-τ activity. WHI-P154 and Lestaurtinib also block the signaling cascade crucial to IFN-τ's function by inhibiting JAK3 and JAK kinases, respectively.
Further along the signaling pathway, chemicals such as S3I-201, Fludarabine, and Pimozide inhibit the phosphorylation and dimerization of STAT proteins directly. S3I-201 prevents STAT3 phosphorylation and dimerization, while Fludarabine inhibits DNA synthesis and has been shown to block STAT1 phosphorylation, a step necessary for IFN-τ signal transduction. Pimozide inhibits STAT5 phosphorylation, thereby obstructing the functional activity of IFN-τ. Moreover, Dasatinib, while primarily known for its inhibition of BCR-ABL tyrosine kinase, also inhibits SRC family kinases and consequently can interrupt downstream signaling of IFN-τ. SH-4-54, a potent STAT3 inhibitor, prevents IFN-τ from exerting its effects by directly inhibiting STAT3 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $153.00 $332.00 | 59 | |
As IFN-τ signals through the JAK-STAT pathway, inhibition of JAK can prevent the phosphorylation and activation of STAT proteins, which are essential for signal transduction initiated by IFN-τ, leading to the functional inhibition of IFN-τ signaling. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG490 is a tyrosine kinase inhibitor that targets JAK2 kinase. By inhibiting JAK2, AG490 can block the JAK-STAT pathway, which is necessary for IFN-τ signal transduction, thereby inhibiting IFN-τ's functional activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib is a selective JAK1 and JAK2 inhibitor. By inhibiting JAK enzymes, it disrupts the JAK-STAT signaling cascade that IFN-τ utilizes, leading to inhibition of IFN-τ mediated actions. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
Fedratinib inhibits JAK2, and indirectly affects the JAK-STAT pathway, which is crucial for IFN-τ signaling. This results in the functional inhibition of IFN-τ. | ||||||
WHI-P 154 | 211555-04-3 | sc-204395 sc-204395A | 10 mg 50 mg | $150.00 $630.00 | 3 | |
WHI-P154 is a JAK3 inhibitor that can block the JAK-STAT signaling pathway, thereby inhibiting the functional activity of IFN-τ, which relies on this pathway for effecting cellular responses. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $148.00 | 104 | |
S3I-201 blocks STAT3 phosphorylation and dimerization, a process that is essential for IFN-τ signaling. By inhibiting STAT3, this compound can suppress IFN-τ's functional activity. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $57.00 $200.00 | 15 | |
Fludarabine is a nucleotide analog that can inhibit DNA synthesis. It has been shown to inhibit STAT1 phosphorylation, which is a necessary step in IFN-τ signal transduction, thus inhibiting IFN-τ's activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib, while primarily a BCR-ABL tyrosine kinase inhibitor, has been shown to broadly inhibit SRC family kinases and can interrupt the downstream signaling of IFN-τ, leading to functional inhibition. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $270.00 $320.00 $600.00 | 3 | |
Lestaurtinib is a tyrosine kinase inhibitor that, by inhibiting the JAK-STAT pathway, can suppress the signaling cascade initiated by IFN-τ, resulting in the inhibition of IFN-τ's activity. | ||||||
Pimozide | 2062-78-4 | sc-203662 | 100 mg | $102.00 | 3 | |
Pimozide is known to inhibit STAT5 phosphorylation, which can be essential for IFN-τ signaling through the JAK-STAT pathway, thus functionally inhibiting IFN-τ. | ||||||